Shen Yao-Hua, Drzymalski Dan M, Zhu Bin-Xiang, Lin Su-Feng, Tu Fang-Qin, Shen Bei, Xiao Fei
Department of Anesthesia, Hangzhou City Linping District Maternal and Child Care Hospital, Hangzhou, China.
Department of Anesthesiology and Perioperative Medicine, Tufts Medical Center, Boston, MA, United Staes.
Front Pharmacol. 2023 Aug 10;14:1205301. doi: 10.3389/fphar.2023.1205301. eCollection 2023.
The combination of ropivacaine and dexmedetomidine has been used as an epidural analgesic for inducing labor. However, there is limited data regarding the administration of epidural analgesia for labor maintenance, hence, this study aimed to determine the optimum concentration through dose-response curves of ropivacaine plus dexmedetomidine, which could be used along with the Programmed Intermittent Epidural Bolus (PIEB) technique. One hundred parturients were randomized into 4 groups who were administered four different doses of ropivacaine (dexmedetomidine at 0.4 μg mL): 0.04%, 0.06%, 0.08%, and 0.1%. The primary outcome that was determined included the proportion of patients experiencing breakthrough pain during their 1st stage of labor. Breakthrough pain was described as a visual analog scale [VAS] score of >30 mm, requiring supplemental epidural analgesia after the administration of at least one patient-controlled bolus. The effective concentration of analgesia that was used for labor maintenance in 50% (EC50) and 90% (EC90) of patients were calculated with the help of probit regression. Secondary outcomes included epidural block characteristics, side effects, neonatal outcomes, and patient satisfaction. The results indicated that the proportion of patients without breakthrough pain was 45% (10/22), 55% (12/22), 67% (16/24), and 87% (20/23) for 0.04%, 0.06%, 0.08%, and 0.10% doses of the analgesic that were administered, respectively. The EC50 value was 0.051% (95% confidence interval [CI], 0.011%-0.065%) while the EC90 value was recorded to be 0.117% (95% CI, 0.094%-0.212%). Side effects were similar among groups. A ropivacaine dose of 0.117% can be used as epidural analgesia for maintaining the 1st stage of labor when it was combined with dexmedetomidine (0.4 μg mL) and the PIEB technique. https://www.chictr.org.cn/index.aspx, identifier ChiCTR2200059557.
罗哌卡因与右美托咪定联合应用已被用作硬膜外分娩镇痛药物。然而,关于硬膜外镇痛用于分娩维持的相关数据有限,因此,本研究旨在通过罗哌卡因加右美托咪定的剂量 - 反应曲线确定最佳浓度,该浓度可与程序化间歇性硬膜外推注(PIEB)技术联合使用。100名产妇被随机分为4组,分别给予四种不同剂量的罗哌卡因(右美托咪定浓度为0.4μg/mL):0.04%、0.06%、0.08%和0.1%。所确定的主要结局包括产妇在第一产程中经历突破性疼痛的比例。突破性疼痛定义为视觉模拟量表(VAS)评分>30mm,即在至少一次患者自控推注给药后仍需补充硬膜外镇痛。借助概率回归计算出50%(EC50)和90%(EC90)的产妇用于分娩维持的有效镇痛浓度。次要结局包括硬膜外阻滞特征、副作用、新生儿结局和患者满意度。结果表明,给予0.04%、0.06%、0.08%和0.10%剂量镇痛药物时,无突破性疼痛的产妇比例分别为45%(10/22)、55%(12/22)、67%(16/24)和87%(20/23)。EC50值为0.051%(95%置信区间[CI],0.011% - 0.065%),而EC90值为0.117%(95%CI,0.094% - 0.212%)。各组间副作用相似。当罗哌卡因与右美托咪定(0.4μg/mL)及PIEB技术联合使用时,0.117%的罗哌卡因剂量可用于维持第一产程的硬膜外镇痛。https://www.chictr.org.cn/index.aspx,标识符ChiCTR2200059557 。